Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Par announced it has received approval from the Food and Drug Administration (FDA) for its New Drug Application for Vasostrict (vasopressin injection), the first vasopressin injection to be approved.
Vasostrict is indicated to increase blood pressure in adults with vasodilatory shock (eg, post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines. The vasoconstrictive effects of vasopressin are mediated by vascular V1 receptors. Vascular V1 receptors are directly coupled to phopholipase C, resulting in release of calcium, leading to vasoconstriction. In addition, vasopressin stimulates antidiuresis via stimulation of V2 receptors which are coupled to adenyl cyclase.
RELATED: Early Goal-Directed Tx Has No Benefit in Early Septic Shock
Vasostrict is available in a 20 units/mL strength in 25-count cartons. Par has begun shipping the product.
For more information call (800) 828-9393 or visit ParPharm.com.
